X

All News

All News


TAZVERIK® Mechanism of Action

Tazverik is the first and only FDA-approved EZH2 inhibitor. Watch this video to see how Tazverik inhibits both MT and WT EZH2.

06/21/2021
TAZVERIK® (tazemetostat) Interactive Experience

Explore this new interactive resource for a closer look at Taverik efficacy, safety, mechanism of action, and more.

06/21/2021
Immunotherapy Combo Checks Progression in Advanced Melanoma

Researchers have used two immunotherapy drugs to target and block different protein checkpoints, significantly increasing the time before melanoma progressed in new patients with...

Oncology Times - Latest Articles
07/05/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834

Content Feed

Two Doses of COVID-19 Vaccine Appear Necessary to Protect Cancer Patients on Active Treatment

Cancer patients on active treatment had a “pronounced lag” in antibody production after receiving the Pfizer-BioNTech COVID-19 vaccine, researchers reported in JAMA Oncology.

Cancer Therapy Advisor
07/15/2021
The Survival Effect of Radiotherapy on Stage II/III Rectal Cancer in Different Age Groups

This study investigates whether radiotherapy exhibits disparate effects in different age groups of patients with stage II/III rectal cancer.

Frontiers in Oncology
07/28/2021
Weekly Outpatient Palliative Care Interventions Among Patients With Head and Neck Cancer

Over 90% of patients with head and neck cancer receiving curative-intent chemoradiation therapy found weekly palliative care visits to be a valuable addition to their treatment.

The ASCO Post
07/27/2021
Many Pandemic-Driven Changes to Cancer Clinical Trials Should Remain

Among the potential improvements were more efficient study enrollment through secure electronic platforms, direct shipment of oral drugs to patients, remote assessment of adverse events...

Medscape
07/27/2021
Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non–Small-Cell Lung Cancer

The aim of this retrospective study is to investigate the efficacy and safety of anlotinib with and without immunotherapy in NSCLC.

Frontiers in Oncology
07/29/2021
Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection

This study investigates long-term outcomes after liver resection for HCC among patients with HBV/HCV co-infection compared with patients with HBV infection.

Frontiers in Oncology
07/29/2021
Development of Multidrug Resistance in Acute Myeloid Leukemia Is Associated with Alterations of the LPHN1/GAL-9/TIM-3 Signaling Pathway

Here, study investigators prove that latrophilin-1 expression also occurs in the myeloid blasts of patients newly diagnosed with myelodysplastic syndrome when ABCB1 is overexpressed.

Cancers
07/20/2021
Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia

Herein, the lncRNA, LINC00152, is identified to be highly expressed in CD34+ LSCs and is found to regulate the self-renewal of LSCs derived from AML patients.

Frontiers in Oncology
07/06/2021
Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma

The addition of the monoclonal antibody daratumumab to the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone significantly improves OS over lenalidomide/dexamethasone alone..

The ASCO Post
07/25/2021
Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer

This study aims to identify immune-related biomarkers that might predict tumor recurrence in stage Ia-b NSCLC within 40 months after curative resection.

Frontiers in Oncology
07/28/2021
Gankyrin as Potential Biomarker for Colorectal Cancer With Occult Liver Metastases

In this study, the expression of Gankyrin in colorectal cancer patients with liver metastases is investigated to determine its prognosis value.

Frontiers in Oncology
07/28/2021
FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage TNBC

The FDA approves pembrolizumab for high-risk, early-stage TNBC in combination with CT as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

The ASCO Post
07/27/2021
Lack of Intrafollicular Memory CD4 + T Cells is Predictive of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Lack of intrafollicular CD4 expression predicts early failure in FL and combined with FLIPI improves identification of high-risk patients.

Blood Cancer Journal
07/15/2021
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia and Richter’s Transformation

RIC-HSCT yields favorable outcomes for patients with high-risk CLL-RT, especially when performed in early remission.

Blood Advances
07/23/2021
Correlation Between Early Endpoints and Overall Survival in Non–Small-Cell Lung Cancer

Using multiple source databases, study investigators compile a data set including 81 phase II–IV RCTs of patients with non–small-cell lung cancer.

Frontiers in Oncology
07/26/2021
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer

A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial...

The ASCO Post
07/25/2021
Task Force Finalizes New Colorectal Cancer Screening Recommendation

The US Preventive Services Task Force has published a final recommendation statement calling for individuals to get their first CRC screening at age 45 instead of waiting until age 50.

Oncology Times - Latest Articles
07/20/2021
Predictors for Fear of Cancer Recurrence in Breast Cancer Patients Referred to Radiation Therapy During the COVID-19 Pandemic

The outbreak of COVID-19 pandemic has greatly impacted on RT strategy for breast cancer patients, which might lead to increased distressing psychological symptoms.

Frontiers in Oncology
07/26/2021
Disease-Specific Survival of AJCC 8th Stage II Gastric Cancer Patients After D2 Gastrectomy

The purpose of this study is to investigate the independent risk factors for treatment failure in stage II gastric cancer.

Frontiers in Oncology
07/26/2021
Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better

In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter phase III ENGOT/GCIG trial.

The ASCO Post
07/25/2021
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

This phase II cohort from PIVOT-02 study evaluates the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin plus nivolumab in first-line metastatic melanoma.

Journal of Clinical Oncology
07/13/2021
Multi-Omic Analyses of the m5C Regulator ALYREF Reveal Its Essential Roles in Hepatocellular Carcinoma

In a pan-cancer tissue analysis that included HCC, study investigators assessed the expression of ALYREF compared to normal tissues using The Cancer Genome Atlas database.

Frontiers in Oncology
07/23/2021
FDA Grants Regular Approval to Pembrolizumab/Lenvatinib for Advanced Endometrial Carcinoma

The FDA approves pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not MSI-H or dMMR who have disease progression following...

The ASCO Post
07/22/2021
Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients

Optimal PET parameters and imaging time points to prognosticate PFS as well as OS of patients with DLBCL have not been established.

Hemasphere
07/13/2021
Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy

de Boniface et al find that breast-conserving surgery plus RT for women with breast cancer is associated with better survival vs mastectomy with or without RT in analysis adjusting for...

The ASCO Post
07/21/2021
Addition of AKT Inhibitor Ipatasertib to Abiraterone/Prednisolone in mCRPC With PTEN Loss

Study investigators find that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produces a significant improvement in PFS among patients with mCRPC with PTEN loss...

The ASCO Post
07/21/2021
Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer

For patients with resectable stage IIIA NSCLC, neoadjuvant CT with cisplatin and docetaxel followed by surgery resulted in a 1-year EFS rate of 48% in the SAKK 16/00 trial and is an accepted...

Journal of Clinical Oncology
07/12/2021
Chemo After Chemoradiation Does Not Extend Survival in Cervical Cancer

Adding chemotherapy after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and it also leads to additional side effects.

Oncology Times - Latest Articles
07/20/2021
BMI May Not Be Best Obesity Indicator to Assess Risk for Lung Cancer

New research published in the Journal of Thoracic Oncology suggests the method used to calculate how obesity is measured may affect whether it is considered a risk factor for lung cancer.

Oncology Times - Latest Articles
07/20/2021
Addition of Prime-Boost Vaccination Regimen to Atezolizumab in Soft-Tissue Sarcomas Expressing NY-ESO-1

Study investigators find that the addition of the heterologous prime-boost vaccination regimen CMB305 to atezolizumab did not improve survival outcomes in patients with STS expressing...

The ASCO Post
07/21/2021
Nivolumab in Non–Small-Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

Study investigators aim to examine clinical data and baseline blood test results as potential predictive biomarkers for benefit from nivolumab, in advanced non–small-cell lung cancer patients.

Frontiers in Oncology
07/21/2021
Benefits From Moving More, Sitting Less for CRC Survivors

A study shows that CRC survivors experienced better quality of life and less fatigue if they engaged in more moderate to vigorous physical activity and reduced their sedentary behavior.

Medscape
07/19/2021
Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer

Study investigators identify real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine for stage IV HER2+ breast cancer...

The ASCO Post
07/19/2021
HER2-Specific CAR T-Cell Trial Addresses Pediatric Brain and Spinal Cord Tumors

The phase I BrainChild-01 trial is assessing the safety and efficacy of delivering repetitive doses of T cells into the brain or the cerebrospinal fluid of children and young adults with R/R tumors

The ASCO Post
07/19/2021
KIT Inhibitor Combination Shows Efficacy in Refractory GIST

Investigators find that the combination of a type I KIT inhibitor, PLX9486, with the type II inhibitor sunitinib produces clinical benefit and improves PFS rates in patients with GIST.

The ASCO Post
07/19/2021
Anti-PD-1 Antibodies as a Salvage Therapy for Patients With Diffuse Large B Cell Lymphoma Who Progressed/Relapsed After CART19/20 Therapy

In this study, investigators analyze data from five patients with R/R DLBCL who had disease progression or relapse following CART19/20 therapy and then treated with PD-1-blocking antibodies...

Journal of Hematology & Oncology
07/05/2021
FDA Approves Belumosudil for Chronic Graft-vs-Host Disease

The FDA approves belumosudil for adult and pediatric patients aged 12 years and older with chronic GvHD after failure of at least two prior lines of systemic therapy.

The ASCO Post
07/19/2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

Combination therapy with nivolumab and ipilimumab is currently only indicated as first-line therapy in patients with advanced non–small-cell lung cancer.

JAMA Oncology
07/15/2021
Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL

The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with CLL/SLL, based on the primary analysis...

The ASCO Post
07/10/2021
ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC

Among patients with muscle-invasive urothelial carcinoma, the presence of detectable ctDNA after surgery may identify those likely to benefit from adjuvant immunotherapy with the ICI atezolizumab.<

Medscape
07/14/2021
Blood Cancer Patients With COVID-19 Fare Better With Convalescent Plasma

A large, retrospective, multicenter study indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients...

Oncology Times - Latest Articles
07/05/2021
Copanlisib Plus Rituximab Shows Superior Efficacy Over Monotherapy in FL, MZL

Copanlisib when given in combination with rituximab demonstrated superior efficacy when compared to rituximab monotherapy in patients with relapsed FL/MZL, per findings presented at ASH 2021.

Oncology Learning Network
06/15/2021
The Correlation of Next-Generation Sequencing-Based Genotypic Profiles With Clinicopathologic Characteristics in NPM1-Mutated Acute Myeloid Leukemia

The purpose of this study is to analyze the association between NGS genotypic profiles and conventional clinicopathologic characteristics in patients with AML with NPM1 mutation.

BMC Cancer
07/08/2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk AML and First Remission, Treatment, and Outcomes

This study suggests that clinical decisions based on dynamic measurable residual disease might be associated with improved therapy stratification and optimized postremission treatment for patients

JAMA Network
07/07/2021
Pralsetinib Demonstrates High Potency, Promise in Patients With RET+ NSCLC

Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.

Oncology Learning Network
07/19/2021
Novel Model Shows High Predictive Potential in Patients With DLBCL

A novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL, according to research published in the Journa

Hematology Advisor
07/08/2021
Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis

Hypoxia is a driver of the malignant progression in ovarian cancer, which results in poor prognosis.

Frontiers in Immunology
07/19/2021
Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non–Small-Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination

Study investigators aim to build a nomogram to predict lung cancer specific survival of NSCLC patients with ipsilateral pleural dissemination and to compare the impact of primary tumor resection...

Frontiers in Oncology
07/19/2021
Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer

More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. 

The ASCO Post
07/15/2021
Good Survival, Outcomes With TARE for HCC

Patients with HCC can be offered transarterial radioembolization as a safe and effective first-line treatment or adjunct to other locoregional therapies, authors of a large multicenter study report

Medscape
07/19/2021